A portfolio of innovative programs

What we develop

Drug candidates

Sensorion’s mission is to offer innovative therapeutic solutions that provide long-term improvements to the lives of patients suffering from, or at risk of, inner ear disorders. In striving to fill this significant unmet medical and social need, we are continuously developing and optimizing our pipeline, mobilizing our in-house technology platform, scientific expertise, and network of experts.

Program Indication Discovery In vivo PoC Pre-clinical Phase 1 Phase 2 Phase 3 Next milestones
TREAT
SENS-401 SSNHL Sudden Sensorineural Hearing Loss 100 100 100 100 100 0 Exploring partnering options
PREVENT
SENS-401 CIO Cisplatin-Induced Ototoxicity 100 100 100 100 30 0 Patient recruitment completion H1 2025
SENS-401 Cochlear Hearing preservation after cochlear implantation 100 100 100 100 60 0 Clinical Study Report completed
RESTORE
OTOF-GT (SENS-501) Otoferlin deficiency 100 100 100 100 2 0 Completion of the first cohort of patient by year end
GJB2-GT GJB2 related early presbycusis 100 100 10 0 0 0 Preclinical CTA/IND enabling activities
GJB2-GT Pediatric progressive GJB2 related hearing loss 100 100 10 0 0 0 Preclinical CTA/IND enabling activities
GJB2-GT Congenital GJB2 related hearing loss 100 100 10 0 0 0 Preclinical CTA/IND enabling activities

PRODUCTS

Discover all the products

RESTORE

GJB2-GT

Go to the description

RESTORE

OTOF-GT (SENS-501)

Go to the description

PREVENT AND TREAT

SENS-401

Go to the description